Healthcare / Medical DevicesTSXV
$0.31
-0.01 (-3.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-15.2M · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$47M
P/E
3.9x
↓EV/EBITDA
N/A
•ROE
-128.1%
↓Gross Margin
63.2%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+354.7%
FCF CAGR
—
FCF margin
-1997.5%
FCF / Net income
1.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $846194.0 · net income $-13.4M · FCF $-16.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $846194.00 | $846194.00 | $403533.00 | $132766.00 | $9000.00 |
| Net Income | $-13.4M | $-13.4M | $-14.0M | $-9.9M | $-13.3M |
| EBITDA | $-12.6M | $-12.6M | $-13.3M | $-9.0M | $-13.1M |
| EPS | -0.19 | -0.19 | -0.22 | -0.16 | -0.30 |
| Gross Margin | 63.2% | 63.2% | 51.2% | -2.5% | 44.4% |
| Operating Margin | -2210.6% | -2210.6% | -4029.4% | -12142.7% | -142133.1% |
| Net Margin | -1582.8% | -1582.8% | -3478.3% | -7461.3% | -147285.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.06 |
| Current Ratio | 0.55 | 0.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-16.9M | $-16.9M | $-15.2M | $-13.9M | $-12.6M |
| Returns | |||||
| ROE | -128.1% | -128.1% | -93.2% | -37.9% | -226.4% |
| Valuation | |||||
| P/E | 3.88 | 3.88 | — | — | — |
| P/B | 2.12 | 2.12 | 4.81 | 3.95 | 30.13 |
| Growth & Yield | |||||
| Revenue Growth | 109.7% | 109.7% | 203.9% | 1375.2% | — |
| EPS Growth | 13.6% | 13.6% | -37.5% | 46.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.22 → -0.19
Residual
+14.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.